Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

USANA Health Sciences, Inc. (USNA) SEC Filings & Earnings Calls

EquiReason read 13 USANA Health Sciences, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-05 — USANA amended its credit agreement, increasing leverage via a material direct financial obligation..

Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason

USNAUSANA Health Sciences, Inc.Follow USNA — free
Packaged Foods · Consumer Defensive
—
Price chart with a free account
Market cap
257.9M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
3 Nov, in 10 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

5 Oct 20268-K · 1.01, 2.03USANA amended its credit agreement, increasing leverage via a material direct financial obligation.open

Risks flagged

Increased leverage from credit facility amendment; no specific financial impact disclosed.

“Item 2.03: took on a material direct financial obligation, increasing leverage.”
Read the original on SEC EDGAR ↗
13 Aug 202610-QUSANA reported a Q2 net loss of $21.4M vs prior-year profit of $9.7M, with revenue down 5.3% and a $29.1M goodwill impairment in Hiya.open

Figures in the filing · each found in the filing text

Consolidated Net Sales · Q2-2026$223M-5% y/y
Core Nutritional Net Sales · Core Nutritional · Q2-2026$192M-4% y/y
Hiya Net Sales · Hiya · Q2-2026$28M-17% y/y
Rise Net Sales · Rise · Q2-2026$3M+40% y/y
Core Nutritional Active Customers · Core Nutritional · Q2-2026384,000-8% y/y
Hiya Active Monthly Subscribers · Hiya · Q2-2026166,000-17% y/y
Goodwill Impairment Charge · Hiya · Q2-2026$29M
Net Loss Attributable to USANA · Q2-2026$-21M

Risks flagged

Core Nutritional customer attrition

“As of July 4, 2026, we had approximately 384,000 active Customers worldwide in the Core Nutritional business... 418,000... (34,000) (8.1%).” · word for word

Hiya goodwill impairment risk

“the Company recorded a non-cash goodwill impairment charge of $29.1 million during second quarter of 2026.” · word for word

Digital marketing headwinds

“The decrease was driven by a challenging digital marketing environment, which created pressure in both net sales and subscriber growth.” · word for word
Read the original on SEC EDGAR ↗
4 Aug 20268-K · 2.02, 7.01Q2 2026 net sales $223M vs $236M YoY; net loss $(21.4)M including $29.1M impairment; adjusted EPS $(0.07) vs $0.74; guidance cut across all segments.earningsopen

Figures in the filing · each found in the filing text

Net sales · Consolidated · Q2-2026$223M-6% y/y
Net loss · Consolidated · Q2-2026$-21M-321% y/y
Diluted EPS · Consolidated · Q2-2026$-1.16-323% y/y
Adjusted diluted EPS · Consolidated · Q2-2026$-0.07-109% y/y
Adjusted EBITDA · Consolidated · Q2-2026$28M-9% y/y
Core Nutritional Active Customers · Core Nutritional · Q2-2026384,000-8% y/y
Hiya Active Monthly Subscribers · Hiya Health · Q2-2026166,000-17% y/y
Cash and cash equivalents · Consolidated · Q2-2026$169M
Inventory · Consolidated · Q2-2026$95M
Share repurchase authorization remaining · Consolidated · Q2-2026$34M

Guidance

FY2026: Core Nutritional net sales $750M (prev $720-$765M); Hiya net sales $125M (prev $140-$155M); Rise Wellness net sales $35M (prev $65-$80M); Consolidated net sales $910M (prev $925M-$1.0B); Net loss $(11)M (prev $20M-$27M); Diluted EPS $(0.61) (prev $1.11-$1.45); Adjusted diluted EPS $0.76 (prev $1.95-$2.29); Adjusted EBITDA $87M (prev $101M-$109M)

Guidance cut across all segments due to underperformance at Hiya and Rise; management cites temporary challenges but lowered expectations significantly.

Risks flagged

Customer attrition in core business and ventures.

“Core Nutritional active customers down 8% YoY; Hiya subscribers down 17%.”

Impairment charge indicates asset write-downs.

“$29.1M non-cash impairment charge.”

Guidance cut across all segments signals worsening outlook.

“Consolidated net sales guidance cut to $910M from $925M-$1.0B; adjusted EBITDA to $87M from $101M-$109M.”
Read the original on SEC EDGAR ↗
12 May 202610-QNet Sales $250M (+0% y/y); Net Income Attributable to USANA $8M (-20% y/y); Core Nutritional Active Customers 404,000 (-12% y/y)open

Figures in the filing · each found in the filing text

Net Sales · Consolidated · Q1-2026$250M+0% y/y
Net Income Attributable to USANA · Consolidated · Q1-2026$8M-20% y/y
Core Nutritional Active Customers · Core Nutritional · Q1-2026404,000-12% y/y
Hiya Active Monthly Subscribers · Hiya · Q1-2026186,000-17% y/y
Gross Profit Margin · Consolidated · Q1-202676.2%
Diluted EPS · Consolidated · Q1-2026$0.41-16% y/y
Operating Cash Flow · Consolidated · Q1-2026$10M-37% y/y
Cash and Cash Equivalents · Consolidated · Q1-2026$163M
Effective Tax Rate · Consolidated · Q1-202655.0%

Risks flagged

Core Nutritional Customer Decline

“The decrease in Core Nutritional net sales was mainly due to a 12.0% decrease in active Customers” · word for word

Hiya Customer Acquisition Slowdown

“The decrease was primarily the result of a lower customer base and a decrease in customer acquisitions.” · word for word

China Profit Repatriation Risk

“If SAFE or other Chinese regulators introduce new regulations or change existing regulations which allow foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from China to the United States may be limited in the future.” · word for word
Read the original on SEC EDGAR ↗
5 May 20268-K · 2.02, 7.01Q1 2026 net sales flat at $250M; net earnings down 20% to $7.5M; adjusted EPS down 16% to $0.61; active customers declining; reiterates FY2026 guidance across all metrics.earningsopen

Figures in the filing · each found in the filing text

Net sales · Consolidated · Q1-2026$250M0% y/y
Net earnings · Consolidated · Q1-2026$8M-20% y/y
Diluted EPS · Consolidated · Q1-2026$0.41-16% y/y
Adjusted diluted EPS · Consolidated · Q1-2026$0.61-16% y/y
Adjusted EBITDA · Consolidated · Q1-2026$28M-5% y/y
Core Nutritional Active Customers · Core Nutritional · Q1-2026404,000-12% y/y
Hiya Active Monthly Subscribers · Hiya Health · Q1-2026186,000-17% y/y
Core Nutritional net sales · Core Nutritional · Q1-2026$204M-3% y/y
Hiya net sales · Hiya Health · Q1-2026$32M-13% y/y
Rise Wellness net sales · Rise Wellness · Q1-2026$14M+741% y/y

Guidance

FY2026: Core Nutritional net sales $720-765M; Hiya net sales $140-155M; Rise Wellness net sales $65-80M; Consolidated net sales $925M-$1.0B; Net earnings $20-27M; Diluted EPS $1.11-1.45; Adjusted diluted EPS $1.95-2.29; Adjusted EBITDA $101-109M

Company reiterates all FY2026 guidance metrics; management expresses confidence in strategic direction and growth catalysts

Risks flagged

Core customer base declining; active customers down 12% YoY in Core Nutritional and 17% in Hiya

“Core Nutritional Active Customers 404,000 vs 459,000; Hiya Active Monthly Subscribers 186,000 vs 224,000”

Profitability pressure from investment spending and mix shift to lower-margin Rise Wellness

“Net earnings -20%; Adjusted EBITDA -5%; margin compression despite flat revenue”
Read the original on SEC EDGAR ↗
7 Apr 2026DEF 14ACEO transition: Jim Brown stepped down, Kevin Guest reappointed CEO on Jan 8, 2026.open

Figures in the filing · each found in the filing text

Core Nutritional Net Sales (constant currency) · Core Nutritional · FY2025$779M-8% y/y
Core Nutritional Adjusted Operating Profit · Core Nutritional · FY2025$57M
Hiya Net Sales · Hiya · FY2025$132M
Hiya EBITDA · Hiya · FY2025$22M
Consolidated Net Sales Growth · FY20258.3%
Operating Cash Flow · FY2025$22M
Cash and Cash Equivalents · FY2025$158M
Net Income · FY2025$11M-74% y/y
Operating Profit · FY2025$37M-44% y/y
Total Shareholder Return (Cumulative, 5-year) · FY2025$25.00

Risks flagged

Core business revenue decline

“We achieved Fiscal Year 2025 constant currency core nutritional net sales of $779 million, which is an 8.0% decrease compared to Fiscal Year 2024” · word for word

Profitability deterioration

“Net income $ in thousands ... 2025 ... $10,760 ... 2024 ... $42,030”

Low bonus payout signals weak performance

“the Compensation Committee determined that each executive had earned a cash bonus under the 2025 Bonus Plan equal to 14.6% of the executive’s 2025 base salary” · word for word

PSU cancellation indicates missed targets

“As of the end of the vesting period, the market and performance conditions for the 2023 PSUs were not achieved, therefore the 2023 PSUs were cancelled in February 2026.” · word for word

CEO transition uncertainty

“On January 8, 2026, Mr. Brown stepped down as Chief Executive Officer and President and Mr. Guest reassumed the role of Chief Executive Officer while remaining Chairman.” · word for word
Read the original on SEC EDGAR ↗
30 Mar 2026SC 13D/AAmendment No. 11 to Schedule 13D filed by Gull Global Limited and Myron W. Wentz, reporting continued 40.1% beneficial ownership of USANA Health Sciences, Inc. common stock, with no change in intent or transactions in the prior 60 days.SEC ↗
30 Mar 2026SC 13D/AAmendment No. 11 to Schedule 13D filed by Gull Global Limited and Myron W. Wentz, reporting continued 40.1% beneficial ownership of USANA Health Sciences, Inc. common stock, with no change in intent or transactions in the prior 60 days.SEC ↗
16 Mar 202610-KProduct returns as % of net sales 0.8; Auto Order as % of direct sales product sales volume 62; In-house manufacturing as % of product sales 56open

Figures in the filing · each found in the filing text

Product returns as % of net sales · FY20250.8%
Auto Order as % of direct sales product sales volume · direct sales · FY202562.0%
In-house manufacturing as % of product sales · FY202556.0%

Risks flagged

China regulatory and business model risk

“Our Greater China region accounts for a significant part of our business and expected growth. A decline in sales or customers in this region would harm our business, financial condition and results of operations.” · word for word

FTC regulatory risk for direct selling

“In 2025, the FTC issued a Notice of Proposed Rulemaking ("NPR") and an Advanced Notice of Proposed Rulemaking ("ANPR") regarding potential rules for earnings claims for direct selling companies.” · word for word

Dependence on Brand Partners

“If we are unable to attract and retain active Brand Partners and Preferred Customers, our business may be harmed.” · word for word
Read the original on SEC EDGAR ↗
18 Feb 20268-K · 2.02, 7.01Net sales $226M (+6% y/y); Net loss $-2M; Diluted EPS $-0.10; Guidance: FY2026 net sales guidance of $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29.earningsopen

Figures in the filing · each found in the filing text

Net sales · Q4-2025$226M+6% y/y
Net loss · Q4-2025$-2M
Diluted EPS · Q4-2025$-0.10
Adjusted diluted EPS · Q4-2025$0.60-6% y/y
Adjusted EBITDA · Q4-2025$27M+7% y/y
Net sales · FY2025$925M+8% y/y
Net earnings · FY2025$11M-74% y/y
Diluted EPS · FY2025$0.58-74% y/y
Adjusted diluted EPS · FY2025$1.93-25% y/y
Adjusted EBITDA · FY2025$101M-8% y/y

Guidance

FY2026 net sales guidance of $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29.

Guidance implies modest top-line growth but continued profitability pressure; management optimistic about diversification.

Risks flagged

Core nutritional business active customers declining 15% YoY, indicating structural challenges in direct selling model.

“USANA Active Customers of 387,000, down 15% from 454,000 in prior year.”

Inventory increased 48% to $107M, driven by Rise brand growth and in-sourcing of Hiya production, posing working capital risk.

“Inventory totaled $107 million, an increase of approximately $35 million, or 48% compared to balances at year-end 2024.” · word for word
Read the original on SEC EDGAR ↗
12 Jan 20268-K · 2.02, 7.01Preliminary Net Sales FY2025 $925M; Preliminary Core Nutritional Net Sales FY2025 $777M; Preliminary Hiya Net Sales FY2025 $132M; Guidance: FY2025 preliminary ~$925M vs prior guidance ~$920M; FY2026 guidance $925M-$1.0Bearningsopen

Figures in the filing · each found in the filing text

Preliminary Net Sales FY2025 · FY2025$925M
Preliminary Core Nutritional Net Sales FY2025 · Core Nutritional · FY2025$777M
Preliminary Hiya Net Sales FY2025 · Hiya · FY2025$132M
Preliminary Rise Wellness Net Sales FY2025 · Rise Wellness · FY2025$16M

Guidance

FY2025 preliminary ~$925M vs prior guidance ~$920M; FY2026 guidance $925M-$1.0B

FY2025 slightly above prior guidance; FY2026 guidance reflects core decline but growth in Hiya and Rise Wellness; investments pressure margins.

Risks flagged

Core nutritional business declining; reliance on Hiya and Rise Wellness for growth.

“Core nutritional business expected $720-765M vs ~$777M preliminary FY2025.”

Rise Wellness operating at breakeven; investments may not yield expected returns.

“Operating margins in this business are expected to be at breakeven in fiscal 2026.” · word for word

Fiscal 2026 is a 52-week year, one week less of net sales compared to fiscal 2025, impacting core business.

“Fiscal 2026 is a 52-week year, one week less of net sales compared to fiscal 2025 (impacts the core nutritional business).” · word for word
Read the original on SEC EDGAR ↗
8 Jan 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open

Risks flagged

Leadership transition may cause short-term uncertainty or strategic shifts.

“CEO transition with former CEO returning; no details on compensation or strategic changes.”
Read the original on SEC EDGAR ↗
5 Nov 202510-QUSANA reported Q3 2025 results with consolidated net sales up 6.7% YoY to $213.7M, but direct selling net sales declined 8.7% YoY, and a net loss of $6.5M was recorded due to a sharp increase in the effective tax rate to 65%.earningsopen

Figures in the filing · each found in the filing text

Net Sales · Consolidated · Q3-2025$214M+7% y/y
Net Sales - Direct Selling · Direct Selling · Q3-2025$183M-9% y/y
Net Sales - Hiya · Hiya · Q3-2025$31M
Active Customers - Direct Selling · Direct Selling · Q3-2025388,000-14% y/y
Active Monthly Subscribers - Hiya · Hiya · Q3-2025193,400
Gross Profit Margin · Consolidated · Q3-202577.2%
Net Income (Loss) Attributable to USANA · Q3-2025$-7M
Diluted Earnings (Loss) per Share · Q3-2025$-0.36
Cash and Cash Equivalents · Q3-2025$145M
Operating Cash Flow · 9M-2025$26M-53% y/y

Risks flagged

Direct Selling Customer Attrition

“Active Customers in this region declined 14.4% year-over-year” · word for word

Tax Rate Volatility

“The year-to-date effective tax rate increased to 65.0% from the 43.0% reported in the comparable period of fiscal 2024.” · word for word

Compensation Plan Transition Risk

“While we expected a slowdown during this transition, it was more pronounced than anticipated.” · word for word

China Cash Repatriation Risk

“If SAFE or other Chinese regulators introduce new regulations or change existing regulations which allow foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from China to the United States may be limited in the future.” · word for word
Read the original on SEC EDGAR ↗

USANA Health Sciences, Inc. — questions

What did USANA Health Sciences, Inc. file recently?
13 SEC filings in the last 12 months. Latest: 8-K on 2026-10-05 — USANA amended its credit agreement, increasing leverage via a material direct financial obligation.

Every figure on this page comes from USANA Health Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.